Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate
Pfizer Inc and Taisho Pharmaceutical Co., Ltd. have signed a definitive agreement, which replaces the letter of intent previously signed between the companies, for worldwide (excluding Japan) collaboration to research, develop and commercialize TS-032, a new schizophrenia drug candidate discovered by Taisho, currently in pre-clinical development.
Read more ...
Expanded Labeling for MabCampath® in Europe
The European Commission has granted marketing authorization to MabCampath® (alemtuzumab) for the treatment of patients with B-cell chronic lymphocytic leukemia (B-CLL) for whom fludarabine combination chemotherapy is not appropriate.
Read more ...
New pharmaceutical candidate Lu AA37096 enters Lundbeck's development pipeline
Lundbeck has initiated phase I clinical studies with Lu AA37096 in order to investigate safety, tolerability and the pharmacokinetic profile of the drug in humans. Lu AA37096 has been discovered based on findings with the unique mechanism of action of escitalopram (Cipralex®) but incorporates effects on a number of additional targets in the brain.
Read more ...
Pfizer Completes Sale of Consumer Healthcare Business
Pfizer Inc said that it has completed the sale of its Pfizer Consumer Healthcare business to Johnson & Johnson for $16.6 billion or about $13.5 billion in after-tax proceeds.
Read more ...
Galvus®, a new oral treatment for type 2 diabetes, receives positive opinion
European health authorities have supported changes proposed by Novartis to prescribing information for Galvus® (vildagliptin), opening the way for the formal regulatory approval of these changes as well as the launch in the European Union of this new oral treatment for patients with type 2 diabetes.
Read more ...
Pfizer to Acquire CovX to Extend Biotherapeutics Investment
Pfizer Inc announced it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and metabolic research and a developer of a biotherapeutics technology platform that will enhance Pfizer's biologic portfolio.
Read more ...
European Commission Approves ATRIPLA®
The European Commission has granted marketing authorization for ATRIPLA® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), formally approving ATRIPLA for commercialization in the 27 countries of the European Union, as well as in Norway and Iceland.
Read more ...